Charles River Laboratories International (CRL) Long-Term Deferred Tax (2010 - 2025)

Charles River Laboratories International's Long-Term Deferred Tax history runs 16 years deep, the most recent figure standing at $67.3 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax rose 59.64% year-over-year to $67.3 million; the TTM figure through Dec 2025 stood at $67.3 million (up 59.64% YoY), while the FY2025 annual figure was $67.3 million, up 59.64% from the prior year.
• Long-Term Deferred Tax for Q4 2025 stood at $67.3 million, up from $36.9 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $67.3 million in Q4 2025, with the low at $31.9 million in Q2 2021.
• The 5-year median for Long-Term Deferred Tax is $40.3 million (2021), against an average of $41.1 million.
• The sharpest annual moves came in 2021 and 2025: Long-Term Deferred Tax retreated 25.48% in 2021, then soared 59.64% in 2025.
• Charles River Laboratories International's Long-Term Deferred Tax stood at $40.2 million in 2021, then grew by 2.58% to $41.3 million in 2022, then retreated by 2.38% to $40.3 million in 2023, then gained by 4.72% to $42.2 million in 2024, then jumped by 59.64% to $67.3 million in 2025.
• Business Quant data shows CRL's Long-Term Deferred Tax at $67.3 million in Q4 2025, $36.9 million in Q3 2025, and $46.9 million in Q2 2025.